Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Watson Oxytrol Launch To Focus On Specialists; CSO To Target Primary Care

  • News

Executive Summary

Watson's launch of the Oxytrol overactive bladder transdermal patch will be modeled after Alza's Ditropan XL market entry

You may also be interested in...



Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch

Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May

Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch

Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May

Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge

Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS041177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By